SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!!
IGT 16.66+0.4%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stephen O who wrote (45)1/11/1999 10:27:00 PM
From: Spiney  Read Replies (1) of 86
 
IGT Pharma's AVLB approved by FDA for phase 1 human clinical trials

IGT Pharma Inc IGT
Shares issued 8,819,820 Jan 8 close $0.80
Mon 11 Jan 99 News Release
Mr. Bruce Schmidt reports
The United States Food and Drug Administration has approved a phase I human
clinical trial using IGT's new cancer drug Anhydrovinblastine (AVLB). The
objective of the study is to test the safety and dose ranging parameters of
AVLB in patients with advanced solid tumours including lung cancer, the
most common form of cancer in the United States. The anticipated benefits
of using AVLB as compared to some currently marketed drugs are reduced
toxic side effects and selectively better cancer tumour reduction.
The designated site for the study is Roswell Park Cancer Institute in
Buffalo, New York. Roswell Park is one of the longest standing cancer
facilities in the U.S. and is a National Cancer Institute designated
Comprehensive Cancer Centre.

+++++++++++++++++++++++++++++

This is excellent news we've all been waiting for!
-still only 9 million shares out and into phase 1 clinicals with FDA approval. Financing should follow shortly...and there should be a few analysts scribbling out updates over the next few days and weeks.

spiney
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News